The type 2 diabetes drug, Actos, has been associated with the development of bladder cancer.
Takeda Pharmaceuticals North America is headquartered in Illinois, although the drug was developed when the company was in New Jersey.
Actos use has been suspended in France and Germany.
The American Diabetes Association concluded that adverse health effects reported to the FDA are consistent with as association between pioglitazone (the active ingredient in Actos) and bladder cancer.
The FDA on June 15, 2011 announced that the use of Actos for more than one year may be associated with an increased risk of cancer. When used over one year, there is about a 40% increased risk of bladder cancer when compared with persons not using Actos.
Locks Law Firm is filing its Actos cases in New Jersey. If you or a loved one have been diagnosed with bladder cancer and have taken Actos, please contact the firm immediately.
Back to top
If you would like to schedule a free consultation with a New Jersey, New York or Pennsylvania ACTOS lawyer, contact Locks Law today.